Spruce Biosciences Q3 net loss narrows

Spruce Biosciences

10/11/2025 21:13

Overview

Spruce Biosciences reports Q3 net loss of $8.2 mln, with reduced operating expenses

Company secured $50 mln in private placement financing from healthcare investors

Outlook

Company expects funding to last into Q4 2026

Result Drivers

PRIVATE PLACEMENT - Co completed $50 mln private placement financing to support TA-ERT development

R&D EXPENSES - Decrease in R&D expenses due to cessation of tildacerfont development, focus shifted to TA-ERT

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$8.21 mln
Q3 Income From Operations
-$8.23 mln
Q3 Operating Expenses
$8.23 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Spruce Biosciences Inc is $132.00, about 3.8% above its November 7 closing price of $127.00

Press Release: ID:nBw5SkYNda

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)